Oncotice (Bacillus Calmette-Guérin (Bcg), Tice)

BCG attaches to the bladder lining and is taken up by immune cells, initiating a Th1‑type cytokine response. This activates macrophages, natural killer cells and cytotoxic T‑lymphocytes that attack and eliminate malignant urothelial cells while creating an inflammatory environment that hinders tumour regrowth.

The specific dose and schedule of Oncotice are determined by the prescribing oncologist or urologist based on the patient’s disease stage, prior treatments and clinical guidelines. Dosage information is not standardized in public sources and must be individualized.

Oncotice is not recommended for use in pregnant or breastfeeding women because the safety of intravesical BCG in these populations has not been established. Clinicians should consider alternative therapies and discuss potential risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Oncotice (BCG) is the only approved live‑attenuated bacterial therapy for NMIBC and is considered the standard of care for high‑risk disease. Compared with intravesical chemotherapy agents, BCG provides a stronger immune‑mediated response, leading to lower recurrence rates, but it may have a higher incidence of local inflammatory side effects.

Oncotice must be stored at 2‑8 °C in a refrigerator, protected from light, and should never be frozen or shaken. The product should be kept in its original packaging until reconstitution and used according to the manufacturer’s instructions.

Oncotice is reconstituted with sterile diluent and instilled directly into the bladder via a catheter. The solution is retained for a prescribed dwell time, typically 2 hours, after which it is drained. Administration is performed by a trained healthcare professional in a clinical setting.

The most serious risks include systemic BCG infection or sepsis, disseminated mycobacterial disease, severe allergic reactions, granulomatous prostatitis, and bladder contracture. Patients should be monitored closely for fever, weight loss, respiratory symptoms or any signs of systemic infection.

Oncotice is contraindicated in patients with active urinary tract infection, recent bladder surgery or traumatic catheterisation, severe immunosuppression (e.g., high‑dose steroids, chemotherapy, HIV with low CD4), and those who are pregnant or breastfeeding.